NCCN Guidelines® Insights: Primary cutaneous lymphomas, version 2.2020: Featured updates to the NCCN guidelines Journal Article


Authors: Mehta-Shah, N.; Horwitz, S. M.; Ansell, S.; Ai, W. Z.; Barnes, J.; Barta, S. K.; Clemens, M. W.; Dogan, A.; Fisher, K.; Goodman, A. M.; Goyal, G.; Guitart, J.; Halwani, A.; Haverkos, B. M.; Hoppe, R. T.; Jacobsen, E.; Jagadeesh, D.; Lunning, M. A.; Mehta, A.; Olsen, E. A.; Pro, B.; Rajguru, S. A.; Shanbhag, S.; Shaver, A.; Shustov, A.; Sokol, L.; Torka, P.; Torres-Cabala, C.; Wilcox, R.; William, B. M.; Zain, J.; Dwyer, M. A.; Sundar, H.; Kim, Y. H.
Article Title: NCCN Guidelines® Insights: Primary cutaneous lymphomas, version 2.2020: Featured updates to the NCCN guidelines
Abstract: Mycosis fungoides (MF) is the most common subtype of cutaneous T-cell lymphoma (CTCL), and Sézary syndrome (SS) is a rare erythrodermic and leukemic subtype of CTCL characterized by significant blood involvement. Although early-stage disease can be effectively treated predominantly with skin-directed therapies, systemic therapy is often necessary for the treatment of advanced-stage disease. Systemic therapy options have evolved in recent years with the approval of novel agents such as romidepsin, brentuximab vedotin, and mogamulizumab. These NCCN Guidelines Insights discuss the diagnosis and management of MF and SS (with a focus on systemic therapy).
Journal Title: Journal of the National Comprehensive Cancer Network
Volume: 18
Issue: 5
ISSN: 1540-1405
Publisher: Harborside Press  
Date Published: 2020-05-01
Start Page: 522
End Page: 536
Language: English
DOI: 10.6004/jnccn.2020.0022
PUBMED: 32380458
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 1 June 2020 -- Source: Scopus
Altmetric
Citation Impact
MSK Authors
  1. Steven M Horwitz
    412 Horwitz
  2. Ahmet Dogan
    231 Dogan